Moberg Pharma announces issue of U.S. Patent related to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Moberg Pharma announces issue of U.S. Patent related to MOB-015 for the treatment of Onychomycosis

STOCKHOLM, January 11, 2015 -- Moberg Pharma AB (OMX: MOB) today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8,952,070, relating to its topical treatment MOB-015 for onychomycosis. The patent is expected to be in effect until 2032. In September 2014, Moberg Pharma reported positive results from a Phase II study of MOB-015. The new patent comprises composition of matter claims directed to a novel topical formulation of terbinafine, as well as claims directed to methods of treatment of onychomycosis using that novel formulation. The formulation enables enhanced penetration of terbinafine into and through the nail. Oral terbinafine is the gold standard for treatment of onychomycosis but is associated with a risk for severe side effects. Developing a topical terbinafine treatment without systemic side effects has been highly desirable but has previously proven to be challenging. Moberg Pharma has demonstrated, ex vivo as well as in vivo, that MOB-015 delivers high microgram levels of terbinafine into the nail, as well as through the nail plate into the nail bed. A mycological cure rate of 54% and significant clear nail growth were observed in the 24 patients who completed the recent phase II study. The data is compelling, in light of the fact that the majority of the patients had severely affected nails; on average approximately 60% of the nail plate was affected by the infection. Moberg Pharma has estimated the peak sales potential of MOB-015 at $250-500 million. “The approval of the U.S. patent for MOB-015 is a key milestone in our strategic goal to become the No. 1 player in products relating to nail fungus. We are moving forward in discussions with potential industrial as well as financial partners for the phase III program, with the aim of starting phase III in 2016,” said Peter Wolpert, CEO of Moberg Pharma AB. About MOB-015 and Onychomycosis Onychomycosis and related problems has been the main focus of Moberg Pharma since its inception in 2006. The company markets Kerasal Nail®, the leading product in the U.S. over-the-counter (OTC) fungal nail category, through its OTC sales team and through distributors in approximately 30 countries. MOB-015 is a proprietary topical formulation of terbinafine developed internally by Moberg Pharma and builds on the company’s experience from the OTC market. Terbinafine is currently the world’s most widely used oral prescription treatment for onychomycosis and was a blockbuster before patent expiration. Topical administration of terbinafine eliminates concerns of oral treatment, including drug interactions or liver damage, but has previously not been successful due to insufficient delivery of the active substance through the nail. Moberg Pharma’s preclinical and clinical data confirm that MOB-015 delivers effective levels of terbinafine through the nail and into the nail bed. Onychomycosis is a common nail infection caused predominantly by dermatophyte fungi, which typically occurs under the toenail, although fingernails may also be affected.  Approximately 10% of the general population suffers from onychomycosis. In the U.S., MOB-015 targets the attractive prescription market, which, after recent launches of two new topical treatments, is expected to exceed $2 billion in the U.S. alone. The untapped potential is significant since the majority of patients are untreated. About this information Moberg Pharma is disclosing this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 11:00 a.m. (CET) on February 11 2015. For additional information contact: Peter Wolpert, CEO, Telephone: +46 (0)70 - 735 71 35, E-mail: peter.wolpert@mobergpharma.se Anna Ljung, CFO, Telephone: +46 (0)70 – 766 60 30, Email: anna.ljung@mobergpharma.se About Moberg Pharma Moberg Pharma AB (MOB.ST) is a rapidly growing Swedish pharmaceutical company with a direct sales and marketing organization in the U.S. and an extensive distribution network in more than 40 countries. The company’s OTC portfolio includes the brands Kerasal®, Jointflex®, Kerasal Nail®, Domeboro®, Vanquish® and Fergon®. Kerasal Nail® (Nalox™in certain markets outside the U.S.) is the leading product for the treatment of nail disorders in the U.S. and Nordic market. The strategy to expand the portfolio includes acquisitions and in -licensing, as well as internal development with a focus on innovative drug delivery of proven compounds. Moberg Pharma has offices in Stockholm and New Jersey, and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergpharma.com.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sivers Moves Q3 Release to Accommodate U.S. Investors

Updated Category News Views 0

Thanksgiving has a nasty habit of turning perfectly ordinary earnings dates into ghost towns, and Sivers Semiconductors has sensibly stepped around that pothole. The company will publish its third-quarter 2026 interim report on Monday, November 30, rather than Thursday, November 26. That is not a strategy reset, a warning, or some grand corporate mystery. It is a calendar...

Continue Reading
RBI Heads to Morgan Stanley With Plenty to Explain

Updated Category News Views 63

Two executives, one New York stage, and a short calendar gap give Restaurant Brands International a clean chance to address investors without the usual blizzard of quarterly slides. Chief Executive Officer Josh Kobza and Chief Financial Officer Sami Siddiqui are scheduled for a fireside chat at Morgan Stanley's Global Consumer & Retail Conference on December 2, 2026, at...

Continue Reading
Cybersecurity's AI Tailwind Meets a Brutal Market Test

Updated Category News Views 89

Security software caught a bid while the rest of the tape was getting kicked down the stairs. That contrast is the whole story: investors saw Palo Alto Networks deliver a strong fiscal first quarter and raise its fiscal 2027 outlook, then decided cyber defense may be one of the few technology budgets companies cannot casually postpone. With AI helping attackers locate and...

Continue Reading
Prospera’s DFW Culture Win Matters Beyond the Plaque

Updated Category News Views 46

Employee survey ballots rarely make pulses race, but this one deserves more than a lazy shrug. Prospera Financial Services has landed on The Dallas Morning News’ 2026 Top Workplaces DFW list for a second consecutive year, placing in the Top Small Workplaces category. For a boutique independent broker-dealer, that is not meaningless wall décor. The people doing the...

Continue Reading
Early Home Care Signals Families Should Not Ignore

Updated Category News Views 17

A pill organizer sitting untouched can say more than a family conversation ever will. Jay Mann of Amada Senior Care in Richmond points to a hard truth in HelloNation's Nov. 20, 2026 article: the need for in-home support often arrives quietly, disguised as little breaks in routines that everybody would rather wave away. This is not a matter for armchair diagnosis, and...

Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 12

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading
MFB Bancorp Offering Puts Chicago Bank Conversion First

Updated Category News Views 86

A small Chicago thrift is asking investors to fund a corporate makeover, and the fine print matters more than the $10 sticker price. MFB Bancorp has commenced an offering tied to the planned conversion of Mutual Federal Bancorp, MHC from a mutual holding company structure into a stock holding company. This is not some high-growth bank story with a shiny new branch map. It...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 56

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 21

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading
PBS Holiday Special Bets on Apollo 8, Music and Unity

Updated Category News Views 82

A moon mission, a 360-voice choir, and Christmas television make an unusual bundle, but that is precisely why this year’s Tabernacle Choir special has some real staying power. Peace on Earth: Christmas with The Tabernacle Choir is not trying to chase whatever noisy trend is chewing up attention this week. It is building a 90-minute holiday event around Apollo 8,...

Continue Reading

Top 5 Most Recently Viewed Articles

Experience the Magic of Winter Getaways at Inns of Monterey

Updated Category News Views 119

Celebrate Winter at Inns of Monterey Inns of Monterey invites you to celebrate the beauty of the winter season with a variety of memorable experiences. Each of our inns offers a unique charm, allowing guests to select a venue that aligns with their vision of a perfect cozy getaway. Whether you're planning a romantic dinner, a family vacation, or a fun retreat, we have...

Continue Reading
Guardian Metal Adjusts Warrant Share Admission Timeline

Updated Category News Views 117

Guardian Metal Adjusts Warrant Share Admission Timeline Guardian Metal Resources plc (LON:GMET/OTCQB:GMTLF) has recently announced a significant update regarding the timing of its warrant share admissions. A technical error has led the company to postpone the admission of 100,000 new shares on the AIM market. Initially anticipated for January 6, 2025, the new expected...

Continue Reading
ThinkCareBelieve Unpacks NATO's Role and Global Perceptions

Updated Category News Views 155

Understanding NATO's Global Impact In an insightful exploration of NATO's significance, ThinkCareBelieve delves into the complexities surrounding this military alliance. The article addresses common perceptions about NATO's role and challenges the narrative that it solely promotes peace. Instead, it raises critical questions about whether NATO may have an agenda that...

Continue Reading
Understanding Recent Options Trading Activity for UiPath

Updated Category News Views 79

Bearish Signals Emerge in UiPath's Options Trading The options trading scene often serves as a barometer for market mood, and right now, UiPath is giving off some serious bearish vibes. With recent trading actions unfolding, we've dug up 11 trades worth keeping an eye on—here's the lowdown. Market Sentiment Revealed Diving into trader behavior reveals a concerning...

Continue Reading
Entergy's Vision for Sustainable Growth in the Gulf South

Updated Category News Views 200

Entergy's Promoting Economic Growth in Gulf South Region At the recent annual meeting, Entergy's Chair and Chief Executive Officer Drew Marsh emphasized the transformative year the company had in 2024. He expressed optimism about the company's potential for continued growth and its commitment to the Gulf South region. Marsh highlighted the vital role Entergy plays in...

Continue Reading